New pill takes on deadly leukemia in major trial
NCT ID NCT05586074
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HEC73543 (Clifutinib) against standard chemotherapy in 324 adults with a specific type of acute myeloid leukemia (FLT3-ITD) that has come back or not responded to first treatment. The goal is to see if the new drug helps people live longer and achieve remission. Participants are randomly assigned to receive either the new drug or chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, ACUTE MYELOID (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the First Affiliated Hospital,College of Medicine,Zhejiang University
RECRUITINGHanzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.